Skip to main content

Table 3 Risk of a frequent exacerbator with the SNPs and haplotypes of OXSR1 in the non-smoker group

From: Association of genetic variants of oxidative stress responsive kinase 1 (OXSR1) with asthma exacerbations in non-smoking asthmatics

Locus

Exacerbation

 

Genotype (N, %)

Codominant

Dominant

Recessive

CC

CR

RR

Total

OR

P

Pcorr

OR

P

Pcorr

OR

P

Pcorr

rs9839010

Exa < 2

544 (61.7%)

293 (33.3%)

44 (5%)

881 (100%)

0.48 [0–0.86]

0.013

0.131

0.41 [0.2–0.84]

0.015

0.151

0.29 [0.06–1.47]

0.136

1.000

Exa ≥ 2

56 (75.7%)

15 (20.3%)

3 (4.1%)

74 (100%)

         

rs61005484

Exa < 2

778 (88.3%)

101 (11.5%)

2 (0.2%)

881 (100%)

0.86 [0.32–2.27]

0.759

1.000

0.87 [0.32–2.33]

0.779

1.000

0 [0–0]

0.999

1.000

Exa ≥ 2

67 (90.5%)

7 (9.5%)

0 (0%)

74 (100%)

         

rs4955408

Exa < 2

319 (36.3%)

420 (47.7%)

141 (16%)

880 (100%)

1.01 [0.65–1.59]

0.957

1.000

1.12 [0.59–2.13]

0.720

1.000

0.84 [0.34–2.05]

0.702

1.000

Exa ≥ 2

23 (31.1%)

42 (56.8%)

9 (12.2%)

74 (100%)

         

rs1392283

Exa < 2

693 (78.8%)

175 (19.9%)

12 (1.4%)

880 (100%)

0.53 [0.23–1.23]

0.140

1.000

0.43 [0.17–1.1]

0.078

0.784

2.03 [0.2–20.44]

0.547

1.000

Exa ≥ 2

65 (87.8%)

8 (10.8%)

1 (1.4%)

74 (100%)

         

rs112221585

Exa < 2

755 (86.1%)

119 (13.6%)

3 (0.3%)

877 (100%)

1.28 [0–2.81]

0.541

1.000

1.32 [0.59–2.95]

0.506

1.000

0 [0–0]

0.999

1.000

Exa ≥ 2

62 (83.8%)

12 (16.2%)

0 (0%)

74 (100%)

         

rs74919163

Exa < 2

450 (52.1%)

351 (40.6%)

63 (7.3%)

864 (100%)

1.22 [0–2.05]

0.461

1.000

1.29 [0.7–2.37]

0.422

1.000

1.09 [0.24–4.93]

0.912

1.000

Exa ≥ 2

31 (43.1%)

38 (52.8%)

3 (4.2%)

72 (100%)

         

rs1384006

Exa < 2

486 (55.2%)

341 (38.7%)

54 (6.1%)

881 (100%)

0.47 [0–0.83]

0.009

0.094

0.36 [0.18–0.72]

0.004

0.038

0.58 [0.15–2.26]

0.435

1.000

Exa ≥ 2

55 (74.3%)

15 (20.3%)

4 (5.4%)

74 (100%)

         

rs156260

Exa < 2

681 (77.3%)

187 (21.2%)

13 (1.5%)

881 (100%)

1.3 [0.69–2.43]

0.413

1.000

1.51 [0.77–2.98]

0.229

1.000

0 [0–0]

0.999

1.000

Exa ≥ 2

55 (74.3%)

19 (25.7%)

0 (0%)

74 (100%)

         

rs9880223

Exa < 2

778 (88.3%)

101 (11.5%)

2 (0.2%)

881 (100%)

0.86 [0.32–2.27]

0.759

1.000

0.87 [0.32–2.33]

0.779

1.000

0 [0–0]

0.999

1.000

Exa ≥ 2

67 (90.5%)

7 (9.5%)

0 (0%)

74 (100%)

         

rs2298417

Exa < 2

636 (72.3%)

225 (25.6%)

19 (2.2%)

880 (100%)

1.87 [1.13–3.09]

0.015

0.155

1.96 [1.05–3.66]

0.035

0.353

3.41 [0.97–12.01]

0.056

0.560

Exa ≥ 2

47 (63.5%)

22 (29.7%)

5 (6.8%)

74 (100%)

         

rs2011

Exa < 2

575 (65.3%)

270 (30.6%)

36 (4.1%)

881 (100%)

0.43 [0.22–0.84]

0.013

0.131

0.38 [0.17–0.81]

0.013

0.132

0.24 [0.03–2.05]

0.192

1.000

Exa ≥ 2

59 (79.7%)

14 (18.9%)

1 (1.4%)

74 (100%)

         

Exa ≥ 2

0 (0%)

9 (12.2%)

65 (87.8%)

74 (100%)

         

Block1_ht1

Exa < 2

199 (22.6%)

462 (52.4%)

220 (25%)

881 (100%)

0.82 [0.53–1.28]

0.390

1.000

0.69 [0.32–1.49]

0.347

1.000

0.85 [0.43–1.72]

0.660

1.000

Exa ≥ 2

17 (23%)

44 (59.5%)

13 (17.6%)

74 (100%)

         

Block1_ht2

Exa < 2

101 (11.5%)

396 (44.9%)

384 (43.6%)

881 (100%)

0.95 [0.6–1.51]

0.837

1.000

0.86 [0.46–1.58]

0.620

1.000

1.21 [0.43–3.38]

0.718

1.000

Exa ≥ 2

7 (9.5%)

39 (52.7%)

28 (37.8%)

74 (100%)

         

Exa ≥ 2

3 (4.1%)

40 (54.1%)

31 (41.9%)

74 (100%)

         

Block2_ht2

Exa < 2

32 (3.6%)

285 (32.3%)

564 (64%)

881 (100%)

1.34 [0.78–2.3]

0.297

0.891

1.41 [0.75–2.66]

0.289

0.867

1.42 [0.3–6.85]

0.661

1.000

Exa ≥ 2

2 (2.7%)

24 (32.4%)

48 (64.9%)

74 (100%)

         
  1. CC common allele homozygote, CR heterozygote, RR minor allele homozygote, SE standard error of mean, Pcorr corrected P value for multiple comparisons
  2. Pcorr corrected P values using the effective number of independent marker loci (MeffLi) calculated by SNPSpD for each SNP (MeffLi = 10.03501), and using the number of haplotypes (n = 3) for each haplotypes
  3. *Adjusted for age, sex, serum total IgE level, predicted FEV1% at the first visit, and total ICS and systemic steroid dose in the 1st year of visit as covariates